Additionally, CSPG4 (also known as NG2) has been reported previously to be frequently expressed in both IDH-mutant and WT GBM, but not lower grade astrocytomas pointing toward its prognostic and therapeutic relevance as a tumor-associated antigen for antibody-based immunotherapy (61). The gene discussed is CSPG4; the disease is glioblastoma.